CN112969710A - Spd-1变异体-fc融合蛋白 - Google Patents

Spd-1变异体-fc融合蛋白 Download PDF

Info

Publication number
CN112969710A
CN112969710A CN201980060042.5A CN201980060042A CN112969710A CN 112969710 A CN112969710 A CN 112969710A CN 201980060042 A CN201980060042 A CN 201980060042A CN 112969710 A CN112969710 A CN 112969710A
Authority
CN
China
Prior art keywords
spd
variant
domain
fusion protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980060042.5A
Other languages
English (en)
Chinese (zh)
Inventor
阿曼都·J·基耶西亚
踏德·A·阿基雷拉
米哈利斯·S·卡利欧利斯
嫪钰
考史克·赞卡尔
张欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axel Biopharmaceutical Co ltd
Leland Stanford Junior University
Original Assignee
Axel Biopharmaceutical Co ltd
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axel Biopharmaceutical Co ltd, Leland Stanford Junior University filed Critical Axel Biopharmaceutical Co ltd
Publication of CN112969710A publication Critical patent/CN112969710A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980060042.5A 2018-09-14 2019-09-12 Spd-1变异体-fc融合蛋白 Pending CN112969710A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US62/731,488 2018-09-14
US201962888320P 2019-08-16 2019-08-16
US62/888,320 2019-08-16
PCT/US2019/050742 WO2020056085A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Publications (1)

Publication Number Publication Date
CN112969710A true CN112969710A (zh) 2021-06-15

Family

ID=68211179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060042.5A Pending CN112969710A (zh) 2018-09-14 2019-09-12 Spd-1变异体-fc融合蛋白

Country Status (11)

Country Link
US (2) US11498955B2 (https=)
EP (1) EP3850003A1 (https=)
JP (1) JP2021535761A (https=)
KR (1) KR20210058902A (https=)
CN (1) CN112969710A (https=)
AU (1) AU2019338416A1 (https=)
CA (1) CA3109983A1 (https=)
NZ (1) NZ774126A (https=)
SG (1) SG11202101904UA (https=)
TW (2) TWI815964B (https=)
WO (1) WO2020056085A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
EP4243852A4 (en) * 2020-11-13 2024-12-11 Ludwig Institute for Cancer Research Ltd PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
US20240141014A1 (en) * 2021-03-03 2024-05-02 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
US20250115657A1 (en) * 2021-05-28 2025-04-10 Akso Biopharmaceutical, Inc. Bispecific FC Fusion Proteins with sPD-1 and IL-15
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557769B2 (en) * 2007-08-03 2013-10-15 Eli Lilly And Company Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
WO2017055547A1 (en) * 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
US20180125934A1 (en) * 2015-04-06 2018-05-10 The Board Of Trustees Of The Leland Stanford Junior University Receptor-Based Antagonists of the Programmed Cell Death 1 (PD-1) Pathway
US20180179263A1 (en) * 2015-06-05 2018-06-28 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261217B (zh) * 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
US20150368316A1 (en) 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
US9546206B2 (en) * 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
US12065476B2 (en) * 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557769B2 (en) * 2007-08-03 2013-10-15 Eli Lilly And Company Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
US20180125934A1 (en) * 2015-04-06 2018-05-10 The Board Of Trustees Of The Leland Stanford Junior University Receptor-Based Antagonists of the Programmed Cell Death 1 (PD-1) Pathway
US20180179263A1 (en) * 2015-06-05 2018-06-28 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
WO2017055547A1 (en) * 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
CN108290953A (zh) * 2015-10-02 2018-07-17 西福根有限公司 抗pd-1抗体和组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAUTE R. L.等: "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 47, pages 6506 - 6514 *

Also Published As

Publication number Publication date
TW202023604A (zh) 2020-07-01
NZ774126A (en) 2023-05-26
SG11202101904UA (en) 2021-04-29
US20230131056A1 (en) 2023-04-27
AU2019338416A1 (en) 2021-04-29
US11498955B2 (en) 2022-11-15
TWI815964B (zh) 2023-09-21
CA3109983A1 (en) 2020-03-19
JP2021535761A (ja) 2021-12-23
WO2020056085A1 (en) 2020-03-19
TW202348622A (zh) 2023-12-16
EP3850003A1 (en) 2021-07-21
US20200181231A1 (en) 2020-06-11
KR20210058902A (ko) 2021-05-24

Similar Documents

Publication Publication Date Title
US20230055445A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US20230131056A1 (en) sPD-1 VARIANT – FC FUSION PROTEINS
US11613587B2 (en) Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
JP7273453B2 (ja) ＩＬ－１５／ＩＬ－１５ＲアルファＦｃ融合タンパク質およびＰＤ－１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
US11524991B2 (en) PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
JP2021522175A (ja) Ｉｌ−１５／ｉｌ−１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
JP2020529832A (ja) ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
CN115768473A (zh) 靶向ox40和fap的双特异性抗原结合分子
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
TW201806972A (zh) 雙特異性結合蛋白
TW202233673A (zh) 含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
JP2023547506A (ja) Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
HK40053326A (en) Spd-1 variant - fc fusion proteins
RU2785993C2 (ru) ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC
NZ796397A (en) sPD-1 variant - Fc fusion proteins
TW202444750A (zh) 抗pdl1單域抗體、融合蛋白及其用途
CN120603853A (zh) 针对muc17和cd3的双特异性抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053326

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20210615

RJ01 Rejection of invention patent application after publication